ChemLifeIntel/Companies/Henry M. Jackson Foundation for the Advancement of Military Medicine

Henry M. Jackson Foundation for the Advancement of Military Medicine

HIGH RISKHQ: — · Private · Founded —

LISTINGPrivateFOUNDED0

FOCUS THERAPY AREAS

Manufacturer

COMPANY INTELLIGENCE SNAPSHOTlive

Manufacturing Sites

Intelligence Briefs

Active Regulatory Actions

—

HQ Country

NO ACTIVE REGULATORY ACTIONSClean compliance footprint across 0 monitored sites · HQ

View regulatory detail

INTELLIGENCE

Showing 2 of 2 briefs on Henry M. Jackson Foundation for the Advancement of Military Medicine

CLINICAL & PIPELINE·Clinical Trial Completion

Retina Research Foundation Completes Phase I/II Study for Ranibizumab (Lucentis) in Macular Degeneration

Retina Research Foundation completed a Phase I/II study (NCT00467935) for ranibizumab (Lucentis) in advanced wet Macular Degeneration. This trial investigated scotoma reduction and improved visual function in 20 patients, concluding in November 2007. The findings contribute to the understanding of anti-VEGF therapies for AMD, informing future R&D strategies and procurement decisions for ophthalmic treatments, highlighting ongoing innovation in this critical therapeutic area.

90-Day Activity

Henry M. Jackson Foundation for the Advancement of Military MedicineLucentisHSN 3002.15

CMCatherine Morrow· Senior Regulatory Intelligence Analyst

12d ago

CLINICAL & PIPELINE·Clinical Trial Initiation

Henry M. Jackson Foundation Initiates Phase 1 Trial for Novel HIV Remission Strategy with Broadly Neutralizing Antibodies and Therapeutic Vaccination

The Henry M. Jackson Foundation for the Advancement of Military Medicine has initiated a Phase 1 clinical trial (NCT06484335) for HIV remission. This study combines broadly neutralizing antibodies (VRC07-523LS, PGDM1400LS) with therapeutic vaccination, targeting safety and viral load setpoint during treatment interruption. This early-stage development signals potential long-term shifts in HIV management strategies.

90-Day Activity

Henry M. Jackson Foundation for the Advancement of Military Medicine

MKMeera Krishnan· Senior Regulatory Intelligence Analyst

2026-06-22